Revance Therapeutics, Inc. (NASDAQ:RVNC) CEO L Daniel Browne sold 7,600 shares of the firm’s stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $24.94, for a total transaction of $189,544.00. Following the completion of the sale, the chief executive officer now owns 133,188 shares in the company, valued at $3,321,708.72. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.
L Daniel Browne also recently made the following trade(s):
- On Wednesday, October 18th, L Daniel Browne sold 7,662 shares of Revance Therapeutics stock. The shares were sold at an average price of $26.16, for a total transaction of $200,437.92.
- On Wednesday, September 20th, L Daniel Browne sold 7,600 shares of Revance Therapeutics stock. The shares were sold at an average price of $23.58, for a total transaction of $179,208.00.
Revance Therapeutics, Inc. (RVNC) opened at $26.50 on Monday. Revance Therapeutics, Inc. has a 1 year low of $15.85 and a 1 year high of $28.75.
Revance Therapeutics (NASDAQ:RVNC) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.95) by ($0.06). The company had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.05 million. Revance Therapeutics had a negative net margin of 37,161.00% and a negative return on equity of 67.85%. The business’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.64) earnings per share. equities research analysts forecast that Revance Therapeutics, Inc. will post -3.73 earnings per share for the current fiscal year.
Institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC purchased a new position in Revance Therapeutics during the 3rd quarter worth approximately $144,000. Bank of America Corp DE raised its position in Revance Therapeutics by 29.5% during the 1st quarter. Bank of America Corp DE now owns 7,247 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 1,651 shares during the last quarter. Legal & General Group Plc raised its position in Revance Therapeutics by 8.1% during the 2nd quarter. Legal & General Group Plc now owns 5,815 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 438 shares during the last quarter. Trexquant Investment LP purchased a new position in Revance Therapeutics during the 2nd quarter worth approximately $231,000. Finally, Voya Investment Management LLC purchased a new position in Revance Therapeutics during the 2nd quarter worth approximately $274,000. 89.14% of the stock is owned by hedge funds and other institutional investors.
A number of analysts have recently weighed in on the stock. BidaskClub cut shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Zacks Investment Research lowered shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, August 12th. Mizuho assumed coverage on shares of Revance Therapeutics in a research report on Thursday, November 16th. They issued a “buy” rating and a $37.00 price objective for the company. JMP Securities assumed coverage on shares of Revance Therapeutics in a research report on Tuesday, August 22nd. They issued an “outperform” rating and a $34.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Revance Therapeutics in a research report on Tuesday, September 26th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Revance Therapeutics has an average rating of “Buy” and a consensus target price of $35.50.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.